Comparative Pharmacology
Head-to-head clinical analysis: DYCLOPRO versus FLURBIPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYCLOPRO versus FLURBIPROFEN.
DYCLOPRO vs FLURBIPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diclofenac epolamine inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and consequent inflammation, pain, and fever.
Cyclooxygenase (COX) inhibitor, reducing prostaglandin synthesis; nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects.
50 mg intravenously every 8 hours
Oral: 50-100 mg every 6-8 hours; maximum 300 mg/day. Ophthalmic: 1 drop every 30 minutes starting 2 hours before surgery, then 1 drop every 4-6 hours for 24-48 hours post-surgery.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in adults with normal renal function; may be prolonged in renal impairment (up to 8-12 hours).
Clinical Note
moderateFlurbiprofen + Gatifloxacin
"Flurbiprofen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateFlurbiprofen + Rosoxacin
"Flurbiprofen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateFlurbiprofen + Levofloxacin
"Flurbiprofen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateFlurbiprofen + Trovafloxacin
Terminal elimination half-life: 3-4 hours (healthy adults) in short-term use; prolonged to 6-12 hours in elderly or renal impairment.
Primarily renal (approximately 70% as unchanged drug and metabolites); biliary/fecal excretion accounts for about 30%.
Renal: 70% as conjugated metabolites (e.g., glucuronides) and <5% unchanged; biliary/fecal: 30%, with enterohepatic circulation.
Category C
Category D/X
NSAID
NSAID
"Flurbiprofen may increase the neuroexcitatory activities of Trovafloxacin."